ATP-binding cassette transporter A1 (ABCA1) mediates the rate-limiting step in
high density lipoprotein (HDL) particle formation, and its expression is regulated primarily by
oxysterol-dependent activation of
liver X receptors. We previously reported that ABCA1 expression and HDL formation are impaired in the lysosomal
cholesterol storage disorder
Niemann-Pick disease type C1 and that plasma HDL-C is low in the majority of
Niemann-Pick disease type C patients. Here, we show that ABCA1 regulation and activity are also impaired in
cholesteryl ester storage disease (CESD), caused by mutations in the LIPA gene that result in less than 5% of normal
lysosomal acid lipase (LAL) activity. Fibroblasts from patients with CESD showed impaired up-regulation of ABCA1 in response to
low density lipoprotein (
LDL) loading, reduced
phospholipid and
cholesterol efflux to
apolipoprotein A-I, and reduced α-HDL particle formation. Treatment of normal fibroblasts with
chloroquine to inhibit LAL activity reduced ABCA1 expression and activity, similar to that of CESD cells.
Liver X receptor agonist treatment of CESD cells corrected ABCA1 expression but failed to correct
LDL cholesteryl ester hydrolysis and
cholesterol efflux to
apoA-I.
LDL-induced production of
27-hydroxycholesterol was reduced in CESD compared with normal fibroblasts. Treatment with
conditioned medium containing LAL from normal fibroblasts or with recombinant human LAL rescued ABCA1 expression,
apoA-I-mediated
cholesterol efflux, HDL particle formation, and production of
27-hydroxycholesterol by CESD cells. These results provide further evidence that the rate of release of
cholesterol from late endosomes/lysosomes is a critical regulator of ABCA1 expression and activity, and an explanation for the
hypoalphalipoproteinemia seen in CESD patients.